Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
4 - CANTEL MEDICAL CORP (0000019446) (Issuer)
Live Leadership Updates
LITTLE FALLS, N.J., Dec. 3, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD) announced today the appointment of Andy Xilas to President, Cantel Dental effective January 1, 2021. He will be taking over for Ken Serota, who will be stepping down as President effective December 31, 2020. In addition, Jennifer Naylor has been appointed to the newly created role of Senior Vice President, Infection Prevention and Control Strategy and Education for Cantel. Mr. Xilas and Ms. Naylor both joined Cantel in 2019, as part of Cantel's acquisition of Hu-Friedy and will sit on the Company's Executive Leadership Team. Mr. Xilas has held various positions at Hu-Friedy with increasing responsibility over
SC TO-I/A - CANTEL MEDICAL LLC (0000019446) (Subject)
SC TO-I/A - CANTEL MEDICAL LLC (0000019446) (Subject)
15-12B - CANTEL MEDICAL LLC (0000019446) (Filer)
8-K - CANTEL MEDICAL LLC (0000019446) (Filer)
SC TO-I - CANTEL MEDICAL LLC (0000019446) (Subject)
S-8 POS - CANTEL MEDICAL CORP (0000019446) (Filer)
S-8 POS - CANTEL MEDICAL CORP (0000019446) (Filer)
S-8 POS - CANTEL MEDICAL CORP (0000019446) (Filer)
S-8 POS - CANTEL MEDICAL CORP (0000019446) (Filer)
25-NSE - CANTEL MEDICAL CORP (0000019446) (Subject)
This live feed shows all institutional transactions in real time.
SC 13G - CANTEL MEDICAL LLC (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
SC 13G/A - CANTEL MEDICAL CORP (0000019446) (Subject)
Fastest customizable press release news feed in the world
The Sanitizing Agents Market size is expected to reach 32.34 USD billion by 2029; Sanitizing Agents are a necessary sanitary product for maintaining hygiene and cleanliness in homes and environments PUNE, India, Sept. 21, 2022 /PRNewswire/ -- Sanitation has become an important aspect of the major industrial processes and commercial sectors. Sanitizing agents are being used more frequently to maintain a level of sanitation. The growing awareness of the importance of food product quality is a major reason why demand for sanitizing agents is expected to rise due to their efficiency and cost-effectiveness. Access PDF Sample Report (Including Graphs, Charts & Figures) @ https://exactitudeconsulta
NEW YORK, May 26, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Crocs Inc. (NASD:CROX) will replace Cantel Medical Corp. (NYSE:CMD) in the S&P MidCap 400, and Organogenesis Holdings Inc. (NASD: ORGO) will replace Crocs in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 2, 2021. STERIS plc (NYSE:STE) is acquiring Cantel Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 2, 2021 S&P MidCap 400 Addition Crocs CROX Consumer Discretionary S&P M
The EON™ Portable Dialysis Water System produces high-quality medical water for acute and home hemodialysis use Mar Cor Purification, Inc., a Cantel Medical Corp. (NYSE:CMD) business, announces the launch of the EON™ Portable Dialysis Water System. The portable water purification device uses reverse osmosis (RO) to remove organic and inorganic substances and microbial contaminants from water that feeds into hemodialysis machines to treat hemodialysis patients or related therapies. The water system quickly delivers and efficiently produces medical-grade water for single-patient hemodialysis treatments in hospitals, clinics, skilled nursing centers, and home environments. This press release
LITTLE FALLS, N.J., March 9, 2021 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its second quarter ended January 31, 2021. Second quarter 2021 net sales were $294.0M, up 1.9% compared to the prior year. Excluding the impact from foreign currency, net sales increased by 1.1%; largely a result of heightened demand for Cantel's infection prevention solutions. The Company's entire second quarter was impacted by the reduction of elective procedures driven by the worldwide COVID pandemic. Second quarter 2021 GAAP earnings per diluted share increased to $0.27, compared to a GAAP loss per diluted share of $(0.05) in the prior year period. GAAP earnings per d
LITTLE FALLS, N.J., Feb. 25, 2021 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD) will release the results for its second quarter ended January 31, 2021 on Tuesday, March 9, 2021 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET. To participate in the conference call, dial 1-888-506-0062 (US & Canada) or 1-973-528-0011 (International) approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Tuesday, March 9, 2021 through midnight on April 9, 2021 by dialing 1-877-481-4010 (US & Canada) or 1-919-882-2331 (International) and using conference ID# 40072. An audio
Complementary to STERIS’s product and service portfolio, focused on infection preventionExtends STERIS’s reach to Dental Customers$110 million in expected EBIT synergies by year fourAccretive to adjusted earnings per diluted share in year oneConference call with STERIS and Cantel management today at 8:00 a.m. ET DUBLIN, IRELAND and LITTLE FALLS, N.J, Jan. 12, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) and Cantel Medical Corp (NYSE:CMD) (“Cantel”) today announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and d
LITTLE FALLS, N.J., Dec. 8, 2020 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its first quarter ended October 31, 2020. First quarter 2021 net sales were $297.0M, up 15.5% compared to the prior year. Excluding the impact from foreign currency, net sales increased by 14.7%, primarily driven by the impact from acquisitions of 16.5% offset by an organic decline of 1.8%. The decline in organic sales was largely the result from the reduction of elective procedures driven by the worldwide COVID pandemic, which impacted the Company's entire first quarter. First quarter 2021 GAAP earnings per diluted share increased 307.1% to $0.57, compared to GAAP earn
LITTLE FALLS, N.J., Dec. 7, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD) and Censis Technologies announced today a new long-term partnership to combine Cantel's leading infection prevention endoscope reprocessing workflow portfolio with the surgical asset management and instrument tracking solutions from Censis. The new enhanced, co-branded software solution will combine the CANEXIS™ Integrated Workflow Solution for Endoscopy from Cantel with Censis' CensiTrac® surgical asset management software to create the leading instrument reprocessing and scope tracking software available to the market. Leveraging Censis' strengths in software development, cloud-based technology, and profes
LITTLE FALLS, N.J., Dec. 3, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD) announced today the appointment of Andy Xilas to President, Cantel Dental effective January 1, 2021. He will be taking over for Ken Serota, who will be stepping down as President effective December 31, 2020. In addition, Jennifer Naylor has been appointed to the newly created role of Senior Vice President, Infection Prevention and Control Strategy and Education for Cantel. Mr. Xilas and Ms. Naylor both joined Cantel in 2019, as part of Cantel's acquisition of Hu-Friedy and will sit on the Company's Executive Leadership Team. Mr. Xilas has held various positions at Hu-Friedy with increasing responsibility over
London, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Meticulous Research®, in its latest publication, titled “Sterilization Equipment Market by Product & Services {Equipment [Heat, Low-temperature (Ozone, Formaldehyde), Filtration), Consumables (Sterilization Indicators, Sterilants), Services (Gamma, Steam)], End User (Hospitals, Pharma)} - Global Forecast to 2027”, states that the sterilization equipment market is expected to grow at a CAGR of 12.2% from 2020 to 2027 to reach $23.73 billion by 2027. Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5141 The growth of the sterilization equipment market is mainly attributed to the growing incidences of